Table 1.
Patient characteristics and immunosuppressive management of de novo anti-GBM disease in pregnancy
| Nillsen [10] | Yankowitz [11] | Deubner [12] | Al-Harbi [13] | Vasiliou [14] | Nair [15] | Joseph [9] | London 2013 | |
|---|---|---|---|---|---|---|---|---|
| Patient characteristics | ||||||||
| Maternal age (years) | 19 | 28 | 21 | 30 | 34 | 23 | 33 | 30 |
| Gestational age (weeks) at presentation | 19 | 3 months pre-pregnancy | 12 | 28 | 18 | 13 | 15 | 25 |
| Previous obstetric history (gravida/parity) | G0 P0 | G0 P0 | G0 P0 | G7 P7 | G1 P0 | G0 P0 | G0 P0 | G2 P1 |
| Relevant past medical history | Possible IgA nephropathy | HTN | ||||||
| Immunosuppressive management | ||||||||
| Timing (pre-pregnancy, during or post-partum) | Post | Pre | Post | During | During | Post | During | During |
| Induction: corticosteroids | (+) | (+) | (+) | (+) | (+) | (+) | (+) | (+) |
| Cyclophosphamide | (+) | (+) | (+) | (−) | (−) | (+) | (−) | (+) |
| Plasmapharesis | (+) (n = NR) | (+) (n = 5) | (+) (n = NR) | (+) (n = NR) | (+) (n = 6) | (+) (n = 14) | (+) (n = 20) | (+) (n = 32) |
| Azathioprine | (−) | (−) | (−) | (−) | (+) | (−) | (+) | (+) |
| Other | None | PO CYC and PRED continued in pregnancy | None | Post-partum management NR | None | None | Low-dose ASA | Azathioprine post-3 IV CYC doses, 32 weeks gestation |
ASA, acetylsalicylic acid; CYC, cyclophosphamide; HTN, hypertension; IV, intravenous; NR, not reported; PCOS, polycystic ovarian syndrome; PO, per oral; PRED, prednisone.